© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Nifuratel traces its roots back to post-war Europe, a period when drug researchers focused on covering gaps in infectious disease treatment. Scientists recognized a growing need for antimicrobials that could tackle both bacteria and fungi without weighing down the body with harsh side effects. Over the decades, this nitrofuran derivative started drawing attention for its reliable performance, especially in obstetrics and gynecology clinics. Researchers persistently tested and improved its formula, responding to emerging resistance in pathogens. While much of the world shifted attention to newer broad-spectrum antibiotics, many European and Asian countries continued to refine and distribute nifuratel. As multi-drug resistant infections became a bigger threat, interest in classic, well-understood compounds like this one gained renewed momentum, keeping its development alive in international labs.
Pharmacies and laboratories know nifuratel as a practical antimicrobial that covers a range of infections. The compound features in tablets, vaginal suppositories, and creams. Unlike single-action antibiotics, it acts on bacteria—Gram-positive and Gram-negative—along with protozoa like Trichomonas vaginalis and even certain fungal pathogens. There’s a reason gynecologists reach for it when patients show mixed infections, uncertain diagnoses, or intolerance to azoles. For chronic, recurring infections, physicians trust it as an alternative to harsher drugs, aware of its relatively gentle safety profile. Generic and branded formulations exist, sold under names like Macmiror and others, depending on the country or manufacturer.
Scientists describe nifuratel as a yellow crystal powder, faintly bitter, stable at room temperature, sparingly soluble in water, and more soluble in organic solvents such as alcohol and acetone. Its molecular formula reads C10H11N3O5S, a fairly compact arrangement given the breadth of action. Key functional groups include a nitrofuran core, responsible for much of its biological activity, and an added thiazole ring that helps enhance antimicrobial performance. Melting point usually hovers around 174–177°C, while decomposition becomes visible at temperatures just above this range. These properties allow flexible formulation into oral or topical agents, which simplifies logistics from manufacturing through to end-user.
Pharmaceutical manufacturers document strict guidelines when packaging nifuratel. Labels must specify the precise content of active substance, most often 500 mg per tablet for adult regimens, or a scaled dose in pediatric and topical forms. Purity needs to meet high standards, sometimes exceeding 99%. Labels carry clear instructions on administration, storage, and key safety warnings, especially to address allergies. The finished product often arrives in blister packs to shield from humidity and light. Packaging information also includes batch numbers and expiration dates, making it easier for clinics and pharmacies to trace any issues back to their origins.
Synthesis of nifuratel follows a well-established path. Chemists start with 5-nitrofurfural, introducing it to thiosemicarbazide under controlled temperature to form the basic hydrazone. Subsequent cyclization incorporates the thiazole ring, with ethanol or a similar solvent carrying the reaction. After purification, the crude product undergoes crystallization to yield the pharmaceutical-grade material. Quality control teams check for residual solvents, impurities, and assess purity benchmarks as dictated by pharmacopeia standards. Some labs have tweaked minor details—catalyst types, purification steps—to optimize yield or improve environmental safety in response to increased regulatory oversight over waste handling.
Nifuratel’s structure enables some degree of chemical modification, though most clinical use sticks to the original molecule. Researchers sometimes investigate minor changes to improve water solubility or target a single infection more efficiently. The nitrofuran group participates in reduction reactions under biological conditions, releasing reactive intermediates. These intermediates are the active entities, capable of binding microbial macromolecules and disrupting key processes—DNA synthesis, cellular respiration, or metabolic enzymes. In the lab, researchers have developed derivatives and analogues for specialized studies, but efforts rarely surpass the stability and overall effect of the parent compound.
Nifuratel appears under several synonyms, reflecting regional naming conventions and different marketing approaches. Alongside its main common name, drug registers often mention Macmiror, as well as longer chemical names like 1-(5-nitro-2-furfurylideneamino)thiosemicarbazide. Labels and academic studies reference all these terms, which sometimes gives the impression of multiple substances. In pharmacies and hospitals, the commercial name usually dominates, so health professionals rarely confuse nifuratel with related nitrofuran drugs, such as furazolidone or nitrofurantoin, that treat other infections.
Doctors and nurses favor nifuratel largely because of its mild safety record. Clinical data demonstrate a comparatively low rate of serious side effects. A minority of patients might face mild gastrointestinal symptoms, and rare allergic reactions. Unlike some antifungaIs and antibiotics, it generally leaves intestinal and vaginal flora relatively undisturbed, reducing risk of secondary yeast infections. European regulators classify it as a prescription-only medication, calling for professional oversight during diagnosis and treatment, to prevent overuse or resistance. Manufacturers adhere to GMP (Good Manufacturing Practice) guidelines, using validated cleaning methods and rigorous batch testing to ensure each dose meets the same standards as the last.
Clinics see most nifuratel use in treating vulvovaginal infections, including mixed infections where patients present symptoms suggesting both trichomoniasis and candidiasis. Doctors prescribe it for recurrent urinary tract complaints, especially in patients who can’t tolerate quinolones or older nitrofurans. Pediatricians sometimes choose it for giardiasis in children who struggle with metronidazole’s metallic taste or potential neurotoxicity. Some regions employ it in combination regimens, pairing it with antifungal agents or probiotics to quickly restore normal microbial balance. Still, individual doctors apply their own judgment, adjusting dosing or drug choices to the patient’s profile. Pharmacies in Europe and Asia keep it on their lists for these reasons, as resistance rates to more common agents climb.
Across academic centers in Italy, Spain, Russia, and China, research teams review how nifuratel fares against major pathogens, including those involved in hospital-acquired infections. Modern studies compare its effectiveness versus traditional competitors, probing whether older drugs retain a meaningful edge in today’s clinics. Microbiologists use routine sensitivity testing to track shifts in resistance, sometimes identifying populations where it continues to work even after other first-line antimicrobials fail. Teams now explore modified release tablets, nanoparticles, and targeted delivery gels to push absorption rates higher and minimize dose frequency, hoping to boost patient compliance.
No drug escapes toxicological review, and nifuratel underwent animal and human studies before moving into daily clinical use. Studies identify very low mutagenic and carcinogenic potential. Dose-ranging trials in rats, mice, and dogs looked for organ-specific toxicity, with most adverse effects only occurring at much higher doses than prescribed to people. Teratogenicity data keeps doctors wary about use in early pregnancy, though adverse outcomes remain rare. Cumulative dosing in chronic or repeated therapy remains a concern, prompting updated guidelines encouraging brief treatment courses. Researchers keep an eye on late developments in metabolic byproducts and their clearance in patients with liver or kidney impairment.
Nifuratel’s profile gains relevance as hospitals scramble to address multi-drug resistant organisms. Companies experiment with fixed-dose combinations, hoping to broaden the market and sidestep resistance trends. As attention swings back to proven, time-tested antimicrobials, opportunity knocks for further investment in this and related molecules. Diagnostic teams in developing countries value reliable, broad-action agents, especially where diagnostic equipment leaves much to be desired. Pharmaceutical chemists continue seeking ways to make production greener and cheaper, reducing impact on workers and the environment. As new data builds from R&D labs, clinical guidelines might expand its use or clarify ideal scenarios for maximum benefit, providing another tool as the world fights microbial threats old and new.
Nifuratel steps onto the pharmacy shelf with a specific job: fighting certain types of infections, especially in the urinary and reproductive systems. Doctors regularly look for ways to help patients clear up stubborn ailments without piling on harsh side effects. Nifuratel gets mentioned more often in parts of Europe and Asia than in the United States, mostly due to regulatory histories rather than a lack of usefulness.
From my own experience following health topics and talking with medical professionals, I’ve noticed patients prize options that go easy on the body yet do the job. In gynecology offices, Nifuratel is valued for handling infections like bacterial vaginosis and trichomoniasis, and it also proves handy for some urinary tract infections. Unlike many broad-spectrum antibiotics that sweep through the body and cause collateral damage to gut bacteria, doctors report that Nifuratel tends to concentrate its punch on harmful microbes, leaving healthy bacteria more or less intact.
The health world prizes treatments that kill off bugs without creating a breeding ground for resistance. Nifuratel has earned respect because it targets protozoa, such as Trichomonas vaginalis, as well as certain bacteria and even yeast. This wide action helps patients who don’t want to play guessing games with what’s causing their discomfort. For women fighting recurring vaginal discomfort, a medication like this—recommended by a qualified physician—can ease the search for relief.
Side effects crop up in any medical conversation. For Nifuratel, the record shows mostly mild problems like stomach upset or skin reactions, and those don’t pop up in every case. Compare that to the disruptive impact antibiotics can have, especially for women dealing with chronic issues, and it becomes clear why doctors see Nifuratel as a valuable arrow in their quiver.
In the United States, Nifuratel remains off the official list of approved medicines, partly due to the way the FDA reviews older drugs and partly because pharmaceutical companies haven’t pushed hard on U.S. trials. This can leave both doctors and patients wishing for more options. In countries where Nifuratel is available, the medical community respects it as a regular choice, not an exotic outlier. The gap highlights a tough truth: geography shapes health options in ways patients can’t always see.
Bacteria and protozoa keep evolving, especially when they face too many drugs too often. Nifuratel’s track record with less resistance, compared to older antibiotics, encourages smarter prescribing. Still, every medication must get used with respect for its power and with a watchful eye on potential problems. Doctors usually call for lab tests before picking Nifuratel, making sure patients get a targeted solution instead of a blanket approach.
One strong step forward lies in education. Patients who understand the cause of their discomfort—be it bacterial, fungal, or protozoan—can better partner with their healthcare providers. Clear diagnosis, smart prescribing, and careful follow-up do more to keep resistance at bay than any single pill ever will.
Nifuratel teaches us the value of tailored treatments that can help many types of infections without causing unnecessary harm. Its story underlines the need to bridge global medicine gaps and share evidence-based solutions everywhere. Supporting ongoing research and making sure healthcare workers and patients have access to tools like Nifuratel—where it makes sense medically—can build a more resilient approach to common and stubborn infections.
Nifuratel shows up on prescriptions across Europe and in other countries for treating infections like vaginitis, trichomoniasis, and some urinary tract infections. Not widely sold in the United States, it often draws questions for people who travel or look beyond local pharmacies. As someone who has spent a fair share of late nights poring over clinical studies and chatting with infectious disease specialists, I know that the way you take a medication can shape your whole treatment experience and outcome.
Doctors usually prescribe nifuratel in tablet form, and they mean business about taking the right dose at the right times. Skipping doses or stopping early opens a door for bacteria or protozoa to bounce back stronger. Clinical research backs up this fact: incomplete courses of infection treatments often lead to resistant strains, making future infections harder to treat. Most prescriptions call for twice-daily doses, with food or after a meal, to keep stomach upset at bay. It’s tempting to take it on an empty stomach for convenience, but I’ve seen plenty of folks regret that after their gut protests.
You start feeling better halfway through the prescription. I get it. The urge to stop early can hit hard once symptoms fade. The problem? Infection can still be lurking beneath the surface. My own family learned the hard way with a urinary tract infection—cutting corners led to round two and even costlier meds later on. Stick with the full round, even if you think you’re out of the woods. If you forget a dose, take it as soon as you remember unless it’s almost time for your next dose. Doubling up rarely ends well and can lead to a range of side effects.
A lot of people ask whether alcohol is off limits. With nifuratel, the research is not as clear-cut as it is with antibiotics like metronidazole—still, doctors often recommend avoiding alcohol until you finish your prescription and symptoms are gone. Alcohol can stress the liver and digestive tract, both of which already work overtime when you fight infection. Also, always let your healthcare provider know what other medications, supplements, or herbal remedies you take. Nifuratel can interact with antifungals, anticoagulants, and even antacids, sometimes in ways doctors only notice after a patient mentions it during a follow-up.
Most folks get through a course of nifuratel without big problems. Mild side effects—nausea, mild stomach upset, a little metallic taste—usually clear up fast. On rare occasions, allergic reactions show up as rash, itching, or swelling. That’s not the moment to tough it out. Call your doctor or pharmacist, even if the symptoms seem minor, because allergies can turn dangerous quickly.
Keep your medication somewhere you check daily—next to your toothbrush or with morning coffee. Setting reminders on your phone works wonders for forgetful moments. For parents, or anyone helping an older loved one, organizing daily doses with a pill organizer makes a huge difference. If language barriers get in the way of understanding instructions, pharmacists can usually print directions in other languages or walk you through step-by-step.
Taking nifuratel as prescribed protects you from repeat illness, limits the risk of resistance, and helps modern medicine keep its edge. It’s not rocket science, but the small daily habits—good timing with food, finishing the whole package, steering clear of booze—add up to better health outcomes. I’ve seen patients come out the other side feeling better, less frustrated, and a lot more confident, just by sticking to these straightforward principles.
Doctors often reach for Nifuratel when infections hit, especially down below with the urinary or vaginal tract. Folks sometimes hear that word and guess it works like other antibiotics, and in some ways it does, but its own quirks set the stage for an honest talk about what the body might face. Anyone picking up a new prescription deserves to know not just the perks, but what bumps might show up along the road.
Most people tolerate Nifuratel just fine, but the body never reads the textbooks. Some notice an upset stomach, which can feel like waves of nausea or send them running to the bathroom with diarrhea. Fatigue sometimes tags along, leaving people puzzled about that sudden droop in energy. Skin rashes pop up on occasion, which for some stays small and for others can turn patchy or itch. Not everyone calls the doctor for a little itch or flush of red, but these aren’t badges of progress—the body is waving a flag.
A bit closer to home for many women, Nifuratel sometimes leads to vaginal itching or discharge. That feels confusing, especially since the medicine aims to clear infections in the first place. Men may feel discomfort with urination, though that’s less common. People with allergies might get hives, swelling, or in very rare cases, trouble breathing. That’s not something to brush off—these symptoms mean the drug doesn’t agree with the immune system and the doctor needs to know.
Here comes the personal side of medicine: side effects change the way people see their own health. A rash or upset stomach might mean many quit medicine early, thinking it’s the lesser of two evils. But stopping without telling the doctor often gives germs a ticket to keep growing. From years around clinics, I’ve seen folks endure small irritations and stay silent. That silence sometimes leads to bigger problems, or leaves doctors puzzled about why the infection won’t clear. Communication beats silent suffering every time.
People with liver or kidney troubles need special watchfulness. Since the drug filters through these organs, old damage or disease can raise the risk of stronger side effects. Seniors also face a bump in risk, as their bodies slow down processing, which lets the medicine linger.
One step that helps more than folks realize is sharing a full medical story with the doctor or pharmacist. This isn’t the time to hide allergy history or leave out supplements. Taking Nifuratel with food can shield the stomach, lowering the chance for nausea or cramps. Not everyone knows that drinking extra water can ease strain on the kidneys. Tracking changes each day helps spot side effects early before they grow.
If any sign of an allergic reaction, especially swelling or trouble breathing, shows up, seeking help fast could save a life. Telling doctors about the smaller stuff, like itchy skin or changes in bathroom habits, helps them decide if it’s safe to keep going or if something else makes more sense.
For anyone worried about side effects, asking honest questions and weighing risks together with the doctor brings confidence. Medicines like Nifuratel solve real problems, but only when safety stays in the mix.
Nifuratel shows up in treatment plans for women’s health issues like urinary tract infections, bacterial vaginosis, and some other vaginal infections. Many doctors prescribe it because it fights a wide range of bacteria as well as yeast. Like many medicines that target infections, it comes with specific considerations for women who are pregnant or breastfeeding.
Looking for reassurance about any drug during pregnancy puts a person on edge. Most want solid studies—on large groups, in places with strong medical ethics—before making decisions. Right now, data on nifuratel’s safety for pregnant or breastfeeding women is thin. Animal studies have not shown obvious harm to a developing fetus when used under typical conditions. But research on humans hasn’t filled in all the blanks.
A handful of observational reports from places like Italy and Eastern Europe suggest that prescribed doses don’t seem to lead to birth defects or complications. Still, these studies don’t represent the level of scrutiny seen with better-known antibiotics. The World Health Organization and major clinical guidelines do not include nifuratel as a first-choice therapy for pregnancy for this reason. Most recommendations say to try safer, better-known options first, where available.
Mothers who breastfeed face another dilemma. Data about how much nifuratel moves into breast milk is scarce. A few small-scale studies detected the drug in breast milk within a short period after dosing, but the long-term effects on infants haven’t come through in research. Because of this, some clinicians hesitate to recommend nifuratel while nursing, especially if other, better-studied antibiotics or antifungals fit the situation.
Weighing treatment options during pregnancy and breastfeeding can’t just follow statistics. Physicians think through every case. An untreated infection sometimes brings greater risk to both mother and baby than potential side effects of medication. For example, ignoring a urinary tract infection while pregnant can lead to kidney infections or trigger early labor.
Every medication has tradeoffs, even the most established ones. Penicillins and cephalosporins have stood up to decades of scrutiny. If a person has allergies to those or has an infection not tackled by the regular options, the doctor might lean on nifuratel—but only after checking other choices and weighing current evidence.
One fact remains clear: more research is needed on nifuratel and similar drugs. Pregnancy combined with infection leaves little margin for error, and most moms want decisions backed up by the strongest evidence. Regulatory authorities should encourage manufacturers to sponsor solid studies of nifuratel in these populations. In the meantime, medical providers can support patients with honesty about what is known, what remains unknown, and which choices match the specific risk profile for mother and child.
Health conversations about nifuratel reflect a bigger struggle in women’s health: much of medicine has yet to catch up to the real-life decisions families make every day. Investing in larger, rigorous clinical studies—especially for medications already in wide use—would build confidence and help patients make the best calls for their own circumstances.
Most folks don't spend much time thinking about how drugs get along inside the body. Toss a new prescription into the weekly lineup, maybe raise an eyebrow at side effects, call it a day. Yet, drug combinations can change everything — sometimes for the better, sometimes not. Nifuratel, a drug used in certain infections, shows this as clearly as any medicine out there.
I once watched my aunt juggle four prescriptions. Nifuratel joined the mix for a stubborn infection. Her doctor pored over a long list of her meds before signing off, not because he doubted Nifuratel's effects, but because combinations could turn simple treatment into a bigger problem. Each medicine pulls on the body in its own way. People trust that doctors catch every clash, but that's not always true, especially with less common drugs like Nifuratel.
Nifuratel is prescribed for things like gynecological and urinary tract infections. It tends not to mess with liver enzymes as much as some antibiotics do, lowering the risk for certain interactions. But that doesn't mean the coast is clear. Patients often take antacids, blood thinners, heart pills, diabetes drugs, and even over-the-counter supplements. At the pharmacy, I've seen folks assume everything in their medicine cabinet plays nicely, but some drug interactions don't show up until the worst moments. Mixing multiple drugs can speed up or slow down how the body breaks down each medication, putting patients at risk for unexpected side effects or not getting the needed benefit.
Reputable medical sources, including the FDA, offer limited data on Nifuratel when combined with other drugs. Many healthcare providers use research from Europe and South America, where the drug is prescribed more often. Still, I remember seeing studies point out that Nifuratel does not seem to cause heavy-duty reactions with most common medicines. It’s good news, but medicine rarely deals in absolutes. Anyone who says otherwise hasn’t spent enough time in a clinic or pharmacy.
People sometimes believe they’d notice a bad reaction right away. That’s wishful thinking. A patient might get dizzy, feel palpitations, or find their infection just won’t go away — only for the cause to trace back to two drugs blocking each other’s effects. In my own family, someone switched brands of a supplement without telling their doctor and spent weeks struggling before a pharmacist noticed the problem.
No one should feel afraid to try a new treatment, but honesty with the prescriber pays off. Bring the full medication list to each appointment, not just the bottles from last month. Online tools, like those on Mayo Clinic or Drugs.com, offer interactive checklists to spot some basic risks. But algorithms miss details a good pharmacist will catch. Pharmacists bridge information gaps, double-checking combinations doctors might not see in busy clinics. Most drugstores welcome questions, and a short conversation can reveal problems before they start.
Mixing Nifuratel with other medications isn’t something to do blindly. For most healthy adults, risky combinations stay rare. Still, the whole medicine cabinet comes into play, so honest communication gives patients their best chance at a smooth recovery.
| Names | |
| Preferred IUPAC name | 1-[(5-nitro-2-furyl)methylthio]-N-methylpropan-2-amine |
| Other names |
Lomexin Macmiror Nifuratelum |
| Pronunciation | /naɪˈfjʊrəˌtɛl/ |
| Identifiers | |
| CAS Number | 4936-47-4 |
| Beilstein Reference | 136164 |
| ChEBI | CHEBI:75183 |
| ChEMBL | CHEMBL2104866 |
| ChemSpider | 15363 |
| DrugBank | DB13634 |
| ECHA InfoCard | 100.123.574 |
| EC Number | EC 3.5.4.- |
| Gmelin Reference | 102946 |
| KEGG | D08241 |
| MeSH | D009687 |
| PubChem CID | 4777 |
| RTECS number | SJ7175000 |
| UNII | 1J9LCK0104 |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C9H13N3O5S |
| Molar mass | 325.313 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.37 g/cm³ |
| Solubility in water | Slightly soluble |
| log P | 0.02 |
| Acidity (pKa) | 5.4 |
| Basicity (pKb) | 2.39 |
| Magnetic susceptibility (χ) | -62.5×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.606 |
| Dipole moment | 6.25 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 354.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -4453 kJ/mol |
| Pharmacology | |
| ATC code | J01XE02 |
| Hazards | |
| Main hazards | May cause allergic reactions; harmful if swallowed; may cause gastrointestinal disturbances. |
| GHS labelling | GHS labelling of Nifuratel: `"Warning; H302; H315; H319; H335"` |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | Keep out of reach of children. If medical advice is needed, have product container or label at hand. Avoid release to the environment. Dispose of contents/container in accordance with local/regional/national/international regulations. |
| NFPA 704 (fire diamond) | NFPA 704: 2-1-0 |
| Flash point | Flash point: 283.4 °C |
| Autoignition temperature | 230 °C |
| Lethal dose or concentration | LD50 (oral, rat): 1200 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Nifuratel: "1200 mg/kg (oral, mouse) |
| NIOSH | Not Listed |
| PEL (Permissible) | Not established |
| REL (Recommended) | 2 g daily |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Nifuroxazide Furazolidone Nitrofurantoin Nitrofurazone |
